[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dianthus Therapeutics Inc (DNTH)

Dianthus Therapeutics Inc (DNTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,361,095
  • Shares Outstanding, K 54,666
  • Annual Sales, $ 2,040 K
  • Annual Income, $ -162,340 K
  • EBIT $ -191 M
  • EBITDA $ -197 M
  • 60-Month Beta 1.20
  • Price/Sales 2,571.13
  • Price/Cash Flow N/A
  • Price/Book 4.34

Options Overview Details

View History
  • Implied Volatility 57.93% (unch)
  • Historical Volatility 66.58%
  • IV Percentile 7%
  • IV Rank 1.96%
  • IV High 229.28% on 08/25/25
  • IV Low 54.50% on 07/01/26
  • Expected Move (DTE 8) 2.89 (2.89%)
  • Put/Call Vol Ratio 0.33
  • Today's Volume 69
  • Volume Avg (30-Day) 178
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 11,201
  • Open Int (30-Day) 10,174
  • Expected Range 97.14 to 102.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.93
  • Number of Estimates 5
  • High Estimate $-0.69
  • Low Estimate $-1.23
  • Prior Year $-0.88
  • Growth Rate Est. (year over year) -5.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.85 +45.29%
on 06/10/26
102.33 -2.25%
on 07/09/26
+15.46 (+18.28%)
since 06/09/26
3-Month
68.85 +45.29%
on 06/10/26
102.33 -2.25%
on 07/09/26
+8.37 (+9.13%)
since 04/09/26
52-Week
18.08 +453.26%
on 08/11/25
102.33 -2.25%
on 07/09/26
+78.94 (+374.30%)
since 07/09/25

Most Recent Stories

More News
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)

NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...

DNTH : 100.03 (+2.00%)
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 ...

DNTH : 100.03 (+2.00%)
Stocks Settle Sharply Lower on Escalating Middle East Tensions

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -1.62%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.87%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.98%. June...

ALK : 50.14 (+5.49%)
GOOGL : 358.89 (-0.84%)
MPC : 283.30 (+0.93%)
AAPL : 316.22 (+0.90%)
FDXF : 154.25 (+7.64%)
TSLA : 406.55 (+3.17%)
FANG : 182.00 (-2.47%)
STX : 890.09 (+3.50%)
WDC : 578.05 (+5.04%)
AMD : 546.72 (+5.67%)
SPY : 751.71 (+0.85%)
META : 631.48 (+4.70%)
Stocks Resume Decline as Chipmakers and AI Companies Fall

The S&P 500 Index ($SPX ) (SPY ) today is down -0.61%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.88%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.80%. June E-mini S&P futures...

ALK : 50.14 (+5.49%)
MPC : 283.30 (+0.93%)
FDXF : 154.25 (+7.64%)
FANG : 182.00 (-2.47%)
WDC : 578.05 (+5.04%)
AMD : 546.72 (+5.67%)
SPY : 751.71 (+0.85%)
ILMN : 193.76 (+3.17%)
SMMT : 15.48 (-1.34%)
MU : 991.64 (+4.52%)
AAL : 17.06 (+3.27%)
QQQ : 723.28 (+1.66%)
Stocks Fall on Weakness in Tech and Trucking Companies

The S&P 500 Index ($SPX ) (SPY ) today is down -0.28%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.38%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.28%. June E-mini S&P futures...

SAIA : 421.29 (+1.60%)
ALK : 50.14 (+5.49%)
UAL : 129.05 (+2.24%)
MPC : 283.30 (+0.93%)
AVGO : 401.11 (+3.20%)
CVX : 174.05 (-1.09%)
HNGE : 89.92 (+1.60%)
CBRL : 49.51 (+1.91%)
FDXF : 154.25 (+7.64%)
$IUXX : 29,727.10 (+1.62%)
ARCB : 150.85 (+3.41%)
ZNU26 : 109-080 (-0.01%)
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...

DNTH : 100.03 (+2.00%)
Dianthus Therapeutics to Participate in Two Investor Conferences

NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform...

DNTH : 100.03 (+2.00%)
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results

Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A  Claseprubart granted...

DNTH : 100.03 (+2.00%)
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform...

DNTH : 100.03 (+2.00%)
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...

DNTH : 100.03 (+2.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Dianthus Therapeutics Inc. is a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics. Dianthus Therapeutics Inc., formerly known as Magenta Therapeutics Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 106.17
2nd Resistance Point 104.25
1st Resistance Point 102.14
Last Price 100.03
1st Support Level 98.11
2nd Support Level 96.19
3rd Support Level 94.08

See More

52-Week High 102.33
Last Price 100.03
Fibonacci 61.8% 70.15
Fibonacci 50% 60.21
Fibonacci 38.2% 50.26
52-Week Low 18.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.